abstract |
There is provided the use of (a) a composition for islet neogenesis therapy comprising a gastrin/cholecytekinin (CCK) receptor ligand and/or an EGF receptor ligand and (b) an agent for suppressing an immune response, for manufacture of a medicament for treating a diabetic subj ect. |